Exhibit 10.1


 


	 	 	 
	 	Form of Contribution and Exchange Agreement	 
	 	 	 
	 	Dated 31 March 2021	 
	 	[____]

    (the Contributor)

    Procaps Group, S.A.

    (the Issuer)

    Crynssen Pharma Group Ltd

    (the Company)

    
	 



 






     


     


    

 


This Agreement (including all schedules, this
“Agreement”) is made on 31 March 2021 by and between:


 


		(1)	[____], a [____] company, located in [____], under registration number [____];



 


(the “Contributor”);


 


		(2)	Procaps Group, S.A., a public limited liability company (société anonyme)
governed by the laws of the Grand Duchy of Luxembourg, with registered office at 9 rue de Bitbourg L-1273 Luxembourg, Grand Duchy of Luxembourg
and in the process of being registered with the Luxembourg Trade and Companies’ Register (Registre de Commerce et des Sociétés,
Luxembourg);



 


(the “Issuer”); and


 


		(3)	Crynssen Pharma Group Ltd, a limited company existing under the laws of Malta, registered with
the Malta Business Registry under number C59671, having its registered office at C1 Midland Micro Enterprise Park, Burmarrad Road, Naxxar,
NXR 6345 Malta;



 


(the “Company”).


 


The Contributor, the Issuer and the Company are
collectively referred to as the “Parties” and individually as a “Party”.


 


Whereas:


 


		(A)	The Contributor holds ordinary shares in the share capital of the Company (the “Contributed Shares”)
as indicated in the table annexed as Schedule 1 to this Agreement.



 


		(B)	On the terms of a business combination agreement dated as of the date of this Agreement and entered into
by and between, inter alios, the Company and the Issuer (the “BCA”), a copy of which is attached as Schedule
2 to this Agreement, it is proposed that (i) all the shareholders of the Company holding ordinary shares of the Company’s issued
share capital (the “Company Shareholders”) contribute all of their ordinary shares in kind to the Issuer in exchange
for new ordinary shares[, and in the case of the Contributor, in exchange for new ordinary shares and redeemable B shares]1
to be issued by the Issuer (the “Exchange”).



 


		(C)	The Contributor has agreed, subject to the
Conditions (as defined in section 2 of this Agreement), to contribute the Contributed Shares to the Issuer against new ordinary shares
[and new redeemable B shares]2 to be issued
by the Issuer in the numbers and proportions as set out in Schedule 3 and having the rights, terms and features set out in the
articles of association of the Issuer, as agreed under the BCA (the “Issued Shares”), with effect on the Exchange
Effective Time (as such term is defined in the BCA) (the “Exchange Effective Time”).



 


		(D)	The Contributor has agreed to pay for the Issued Shares by way of a contribution in kind which consists
of the Contributed Shares (the “Contribution”). The Contribution includes all the rights, commitments and obligations,
known or unknown, which can or could be attached to the Contributed Shares in any manner whatsoever.



 





 







1
Bracketed provision to be included for Contributors receiving redeemable B shares.





2
Bracketed provision to be included for Contributors receiving redeemable B shares.




 






    2


     


    

 


It is agreed as follows:


 


		1	Consent



 


The Contributor agrees to consent (“Contributor
Consent”) to the Exchange and all the transactions contemplated under the BCA and the Transaction Documents (as defined in
the BCA) to which the Contributor is a party, provided that (i) such Contributor Consent shall be expressly conditioned upon this Agreement
and each Transaction Document to which Contributor is or will be a party being performed in accordance with the terms of such agreements,
and to the extent the transactions contemplated by any such agreement referenced in this (i) is not performed in accordance with such
agreement, the Contributor Consent shall automatically terminate, without further action of the Parties, and shall become null and void;
(ii) the BCA and each of the other Transaction Documents not referenced in (i) above being performed in all material respects in accordance
with the terms of such agreements and, to the extent the transactions contemplated by any such agreement referenced in this (ii) is not
performed in all material respects in accordance with such agreement, the Contributor Consent shall automatically terminate, without
further action of the Parties, and shall become null and void; (iii) the Parties will obtain Contributor’s prior written consent
before effecting any proposed amendment, waiver or similar change to the BCA or any other Transaction Document that would reasonably
be expected to adversely impact in any material respects the rights of the Contributor (it being understood that such consent shall be
required in connection with any proposed change to the economic provisions and terms of such agreements that would adversely impact the
Contributor or to the Outside Date (as defined in the BCA)[, including any amendment or waiver to Section 9.03(e) of the BCA that would
result in the SPAC (as defined in the BCA) having less than US$160,000,000 of cash available for distribution immediately following the
Closing) or any amendment or waiver that would reasonably be expected to preclude IFC from fully redeeming its redeemable B Shares immediately
following the Closing]3 and, to the extent
such consent is not obtained, the Contributor Consent shall automatically terminate, without further action of the Parties, and shall
become null and void, and (iv) to the extent the BCA is terminated for any reason or the transactions contemplated by the BCA are not
consummated, the Contributor Consent shall automatically terminate, without further action of the Parties, and shall become null and
void. The Contributor further consents, subject to the conditions set forth in this Section 1, to the contribution and exchange agreements
entered into as of the date hereof by and among each of the other Company Shareholders, the Company and the Issuer, and the transactions
contemplated thereby (the “Other Exchanges”) and agrees to execute and deliver (or cause to be executed and delivered)
any consents required to be delivered to the Malta Business Registry together with the filing of the notification of the share transfers
taking place in connection with the Other Exchanges.


 


		2	Conditions to the Contribution and Issuance
                                            of the Issued Shares



 


		2.1	The obligations of the Parties under clauses 3 and 4 of this Agreement are subject to the satisfaction
or waiver (where permissible) of the conditions set forth in Sections 9.01 and 9.03 of the BCA, including, without limitation, the prior
issuance by a Luxembourg independent auditor (réviseur d’entreprises) engaged by the Issuer, at or before the Exchange
Effective Time, of a report on the contributions in kind relating the Exchange prepared in accordance with article 420-10 juncto article
420-23 (6) of the Luxembourg law on commercial companies dated 10 August 1915 (the “Companies Law”), as amended and
in which it will be stated that the values arrived at by the application of the methods of valuation used to value all the shares of the
Company to be contributed to the Issuer in the Exchange correspond at least to the number and nominal value and the share premium of the
shares to be issued by the Issuer in consideration thereof (the “Conditions”).The Parties acknowledge that the Exchange
shall occur on the Exchange Effective Time for all Company Shareholders simultaneously and the Issuer endeavours and commits on a reasonable
best efforts basis to have the Conditions fulfilled to allow for the Contribution to occur as soon as possible on or after the Merger
Effective Time.



 


		2.2	The Contributor hereby unconditionally and unequivocally waives, for all purposes and effects of law,
all and any pre-emption rights which the Contributor may be entitled to under the Company’s memorandum and articles of association
or under any applicable law or agreement, in connection with the proposed contribution in kind to the Issuer by the other shareholders
of the Company of all their shares held in the issued share capital of the Company to occur simultaneously with the Exchange.



 


 






3
Bracketed provision to be included for Contributors receiving redeemable B shares.


 






    3


     


    

 


		3	Contribution and Issuance of Issued Shares



 


		3.1	On the Exchange Effective Time and subject to the satisfaction or waiver (where permissible) of the Conditions:



 


		(i)	the Contribution shall be contributed to the Issuer (and recorded as share capital and share premium);



 


		(ii)	the Contribution shall be contributed in full and complete satisfaction of the issue and allotment to
the Contributor of the Issued Shares by the Issuer;



 


		(iii)	the Issued Shares shall be issued by the Issuer and allotted to the Contributor;



 


		(iv)	the Issued Shares shall be issued and allotted in full and complete satisfaction of the Contribution;



 


		(v)	the Issued Shares shall be issued and allotted to the Contributor as fully paid shares; and



 


		(vi)	the Issuer shall register the Issued Shares in the name of the Contributor in the Issuer’s share register
as at the date of issue being the Exchange Effective Time.



 


		3.2	The Contributor represents and warrants (i) that it is the sole lawful owner of the Contributed Shares
and that, as of the Exchange Effective Time, the Contributor will be the only person entitled to and having power to dispose of the Contributed
Shares, (ii) that the Contributed Shares are free of any lien, encumbrance, pre-emption rights or other similar rights, other than those
rights that will have been duly waived prior to the Exchange Effective Time [and rights granted to the International Finance Corporation
(“IFC”) pursuant to those certain Pledge Agreements, dated as of September 1, 2017, by and among the Contributor, IFC
and the other parties thereto, which rights shall be released immediately following the Exchange Effective Time]4
and, at the time of the Exchange Effective Time, will be freely transferable and/or assignable to the Issuer and not subject to any third
party rights or other rights attached to the Contributed Shares by virtue of which any person may be entitled to demand that the Contributed
Shares be transferred to him, and (iii) that any and all necessary consents for transfer that may be required under (a) any shareholder
agreement existing between the Contributor and any other shareholders of the Company,(b) articles of association of the Company or (c)
the laws of any applicable jurisdiction will have been complied with or waived (where permissible) prior to the Exchange Effective Time.



 


		3.3	The Contributor represents and warrants that the Contribution will not:



 


		3.3.1	conflict with or violate its organizational or governance documents; or



 


		3.3.2	conflict with or violate any Law (as defined in the BCA) applicable to the Contributor.



 


		3.4	The Contributor represents and warrants that there is no Action (as defined in the BCA) pending or threatened
in writing against the Contributor or any property or asset of the Contributor that would prevent, materially delay or materially impede
the performance by the Contributor of its obligations under this Agreement.



 


		3.5	The Contributor represents and warrants (i) that it has been provided with copies of all the Transaction
Documents, including the contribution and exchange agreements entered into as of the date hereof by and among each other Company Shareholder,
the Company and the Issuer and all other information that the Contributor has requested in connection with its review and investigation
of the Transactions (as defined in the BCA) and (ii) that it approves of and agrees with the calculations set forth in each other Transaction
Documents as of the date hereof.



 





 







4
Bracketed provisions to be included for Contributors that have pledged a portion of the Contributed Shares.






 






    4


     


    

 


		3.6	The Contributor agrees, notwithstanding any rights or privileges the Contributor may have regarding the
ability to Transfer (as defined below) any of the Contributed Shares pursuant to applicable Law (as defined in the BCA), the Company Organizational
Documents (as defined in the BCA), or the Company Shareholders’ Agreements (as defined in the BCA), not to Transfer any of the Contributed
Shares before the earlier of (i) one year from the date hereof and (ii) the implementation of the Exchange or termination of this Agreement
in accordance with its terms. A Transfer or attempted Transfer of any Contributed Shares in breach of this clause 3.6 shall be null and
void and have no effect towards the Company, and the Company shall refuse to record in the share register of the Company any Transfer
or other transaction made on such Contributed Shares and to recognize in that case any right to third parties in or against the Company.
For purposes of this clause 3.6, the “Transfer” of any Contributed Share shall mean the transfer of either or both of the
legal and beneficial ownership in such Contributed Share, and/or the grant of an option or right to acquire either or both of the legal
and beneficial ownership in such Contributed Share, and shall include: (i) any direction (by way of renunciation or otherwise) by a person
entitled to an allotment or issue of any Contributed Share, that such Contributed Share be allotted or issued to some other person; (ii)
any sale or other disposition of any legal or equitable interest in a Contributed Share (including any attached voting right) and whether
or not by the registered holder thereof and whether or not for consideration or otherwise and whether or not effected by an instrument
in writing; (iii) any grant or creation of a Lien (as defined in the BCA) over any Contributed Share; and (iv) any agreement, whether
or not subject to any conditions, to do any of the foregoing.



 


		3.7	The Issuer represents and warrants that the Issued Shares issued to Contributor shall be validly issued
in accordance with the Companies Law and the articles of association of the Issuer, free any lien, encumbrance, pre-emption rights or
other similar rights, other than those rights under the applicable organizational or governance documents of Issuer or that will have
been duly waived prior to the Exchange Effective Time.



 


		3.8	The Issuer represents and warrants that the issuance of the Issued Shares to Contributor will not:



 


		3.8.1	conflict with or violate its organizational or governance documents; or



 


		3.8.2	conflict with or violate any Law (as defined in the BCA) applicable to the Issuer.



 


		3.9	Each of the Company and Issuer represents and warrants that there is no Action (as defined in the BCA)
pending or threatened in writing against such Party or any property or asset of such Party that would prevent, materially delay or materially
impede the performance by such Party of its obligations under this Agreement.



 


		3.10	Each of the Company and Issuer represents and warrants, as applicable, that it has provided to the Contributor
(i) all values used in the calculation of the number of Issued Shares to be issued to Contributor, including all values set out in Schedule
3 and (ii) the opportunity to (a) consult with such Party regarding such values, and (b) propose such reasonable changes or alterations
to such values (or to the calculation of such values) for such Party to approve, such approval not to be unreasonably withheld.



 


		3.11	The Issuer undertakes to enact the notarial deed confirming the share capital increase of the Issuer (acte
de constat d’augmentation de capital) by way of contribution in kind of the Contributed Shares within one month after the subscription
of the Issued Shares by the Contributor, in accordance with article 420-23 of the Companies Law.



 






    5


     


    

 


		4	Power of attorney and commitments



 


		4.1	Subject to the rights of the Contributor set forth in sections 1 and 5, the Contributor hereby instructs,
authorises and empowers any director of the Issuer or any director of the Company, or any lawyer or employee at Arendt & Medernach
SA, Arendt Services SA or Camilleri Preziosi, each of them acting individually and with full power of substitution, as the Contributor’s
true and lawful agent and attorney-in-fact to, provided that, in any case and for the avoidance of doubt, not in a way that would reasonably
be expected to negatively impact the rights of the Contributor:



 


		4.1.1	subscribe for the Issued Shares in exchange for the Contribution in the name and on behalf of the Contributor,
in full compliance with the terms of this Agreement and without prejudice to the Contributor’s rights set forth in sections 4.4
and 4.5 below;



 


		4.1.2	register, in the name and on their behalf, the transfer of the Contribution in the share register of the
Company and the issuance of the Issued Shares in the share register of the Issuer, and perform any and all publication, filing or registration
formalities that may be necessary in relation with the Contribution and issuance of the Issued Shares;



 


		4.1.3	subject to the rights of the Contributor set forth in sections 4.4 and 4.5, determine, in accordance with
Schedule 3 hereof and the other Transaction Documents (as defined in the BCA), the final value of the Contribution, the amount of Issued
Shares and the final amount of share premium of the Issuer to be recorded in the accounts of the Issuer as a result of the Exchange.



 


		4.2	Each Party hereby commits to use its reasonable efforts to:



 


		4.2.1	take all actions and do such things that are reasonably necessary to be taken by such Party to facilitate
and effect the Exchange, the Merger Issuance (as defined under the BCA), the Merger (as defined under the BCA), the restatement of the
articles of association of the Company, the amendment and restatement of the articles of association of the Issuer, and any other transaction
contemplated under the BCA (the “BCA Transactions”);



 


		4.2.2	as applicable (i) attend or have a suitable proxy attend, any meeting or any adjourned meeting of the
general meeting of shareholders of the Company convened for the purpose of implementing any of the BCA Transactions, waive any convening
formalities, vote in the name and on behalf of the Contributor on any resolution submitted to said meeting, sign any documents, shareholder
proxy, written consent or resolutions, delegate under his own responsibility the present proxy to another representative and, in general,
do whatever seems appropriate or useful in connection with the said meeting; and



 


		4.2.3	take such actions and do such things that are reasonably required of such Party to agree or amend the
form, terms and conditions of, to certify any and all documents as certified true copies and to make, sign, execute and do, and all such
deeds, instruments, share registers, agreements, applications, forms, declarations, confirmations, notices, acknowledgements, letters,
certificates, minutes, powers-of-attorney, general assignments, and any other documents relating to and required or desirable to implement
the BCA Transactions by such Party promising ratification.



 


		4.3	The Contributor hereby commits to provide the Issuer and/or Company, promptly upon reasonable request
from the Issuer and/or Company, as applicable, all documents and information which are reasonably required for the purpose of complying
with applicable anti-money laundering laws and regulations (including without limitation the Luxembourg law of 12 November 2004 on the
fight against money laundering and the financing of terrorism as amended) in the context of the implementation of the BCA Transactions
or that would be required from a notary residing in Luxembourg for the same purposes.



 






    6


     


    

 


		4.4	Each of the Issuer and the Company hereby commits, as applicable, to (i) review and consult with the Contributor
on all constituent values and calculations relevant to the economic benefit to be received by the Contributor in connection with the consummation
of this Agreement and the BCA Transactions and not otherwise provided to the Contributor as of the date hereof, including all values set
out on Schedule 3 (the “Issued Shares Calculations”); (ii) provide the Contributor with a copy of such Issued Shares
Calculations within two (2) calendar days of the determination of such Issued Shares Calculations, but in any event, not later than ten
(10) calendar days prior to the Closing (as such term is defined in the BCA); and (iii) allow the Contributor to propose changes or alterations
to the Issued Shares Calculation subject to the approval of the Issuer and/or the Company, as applicable, for such Party to approve, such
approval not to be unreasonably withheld.



 


		4.5	Each of the Issuer and the Company hereby commits, as applicable, to provide to the Contributor as soon
as available and in event prior to Closing: (i) a draft of any Holdco Requisite Approvals (as defined in the BCA), relevant for the consummation
of this Agreement, and (ii) the Second HoldCo Auditor Report (as defined in the BCA) on the contributions in kind relating to the Exchange
Issuances (as defined in the BCA); it being understood that in relation to the matters set forth in point (i) above, the Contributor may
propose changes or alterations subject to the approval of the Issuer and/or the Company, as applicable, for such Party to approve, such
approval not to be unreasonably withheld.



 


		5	Termination



 


This Agreement shall automatically terminate
upon termination of the BCA in accordance with its terms. Without limiting the preceding sentence, termination of the BCA shall be confirmed
and notified in accordance with section 6 hereof by the Company to the Issuer and Contributor at the latest five (5) calendar days following
such termination. In addition, the Contributor shall have the right to terminate this Agreement if the BCA Transactions have not been
consummated by the Outside Date by providing written notice to the other Parties; provided, however, that this Agreement may not be terminated
by or on behalf of any Party that either directly or indirectly is in breach or violation of any representation, warranty, covenant, agreement
or obligations contained herein and such breach of violation is the principal reason giving rise to such Party’s right to terminate
this Agreement.


 


		6	Notices



 


All notices, requests, permissions, waivers
and other communications hereunder shall be in writing in the English language and shall be deemed to have been duly given if signed by
the respective persons giving them (in the case of a company, the signature shall be by an officer thereof) and delivered to the relevant
address or email address (as applicable) as the relevant Party may have notified the other in writing, by:


 


		(i)	hand;



 


		(ii)	deposited in the mail (registered, return receipt requested), properly addressed and postage prepaid;
or



 


		(iii)	email.



 


		7	Entire Agreement – Amendments



 


This Agreement contains the entire understanding
of the parties hereto with respect to the subject matter contained herein, supersedes and cancels all prior agreements with respect hereto
and may be amended only by a written instrument executed by the parties or their respective successors or assigns. The section and clause
headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of
this Agreement.


 






    7


     


    

 


		8	Invalidity



 


If any of the provisions of this Agreement
is held invalid or unenforceable, and unless the invalidity or unenforceability thereof does substantial violence to the underlying intent
and sense of the remainder of this Agreement, such invalidity or unenforceability shall not affect in any way the validity or enforceability
of any other provisions of this Agreement except the invalidated or unenforceable provision. In the event any provision is held invalid
or unenforceable, the Parties shall attempt to agree on a valid and enforceable provision which shall be a reasonable substitute for such
invalid or unenforceable provision in the light of the content of this Agreement and, on so agreeing, shall incorporate such substitute
provision in this Agreement.


 


		9	Counterparts and Signatures



 


This Agreement may be executed in one
or more counterparts. A set of counterparts, containing the signatures of all the Parties hereto, shall between them constitute one single
agreement.


 


Each Party shall receive and keep a copy
of the original in due evidence of this Agreement, the original being kept with the Issuer.


 


		10	Governing Law and Jurisdiction



 


Except for any provisions concerning
the transfer of the Contributed Shares of the Company to the Issuer, this Agreement and any non-contractual obligations arising out of
or in connection with it shall be governed by and construed in accordance with Luxembourg law. The transfer of the Contributed Shares
of the Company or any other related shares or securities created under the laws of Malta shall be governed by the laws of Malta.


 


The Parties irrevocably agree that the
courts of Luxembourg City (Grand Duchy of Luxembourg) have exclusive jurisdiction to settle any dispute which may arise out of or in connection
with this Agreement.


 


		11	Miscellaneous



 


The Parties acknowledge and agree that
for the purposes of Maltese law, insofar as the term “contribution” is used in this Agreement in connection with the shares
held in the issued share capital of the Company, such term shall be construed to refer a transfer of shares and not to a contribution
as contemplated by article 1740B of the Maltese Civil Code, Chapter 16 of the Laws of Malta.


 


This Agreement has been entered into the day and
year first above written.


 


[signature page follows]


 




    8


     


    

 


SIGNATURE PAGE


 


	 	 
	Procaps Group, S.A.	 
	By:	 
	Title:	 



 




    9


     


    

 


	 	 
	Crynssen Pharma Group Ltd	 
	By:	 
	Title:	 



 



    10


     


    

 








	[________]	 	 
	 	 	 
	By	           	 
	Name:	 	 
	Title:	 	 


  




    11


     


    

 


Schedule 1 – Contributed Shares


 


	Contributor	 	Contributed Shares
	 	 	 
	[_____]	 	[_____] ordinary shares in Crynssen Pharma Group Ltd


 




    12


     


    

 


Schedule 2 – Business Combination Agreement


 


[attached]


 




    13


     


    

 


Schedule 3 – Issued Shares


 


[attached]


 


 


14